TAG Degradation Platform

The TAG Degradation Platform (dTAG/aTAG) is a TPD based approach to target validation that uses a heterobifunctional Degrader targeting a fusion protein. This technology allows rapid and highly selective degradation of a protein of interest, and is generalizable to a range of fusion proteins. It is useful as an alternative to genetic methods for target validation and can be used in cell culture or in vivo. The TAG system has potential for validation of targets for which there are no known ligands.

Products
Background
Literature (2)

Ligands

Cat. No. Product Name / Activity
6970 aTAG 2139
Degrader of MTH1 fusion proteins for use within the aTAG system
6605 dTAG-13
Degrades mutant FKBP12F36V fusion proteins; useful alternative to genetic methods for target validation

Other

Cat. No. Product Name / Activity
6971 aTAG 4531
Degrader of MTH1 fusion proteins for use within the aTAG system

The dTAG technique involves the expression of a protein of interest as a fusion with mutant FKBP12F36V via transgene expression or CRISPR-mediated locus-specific knock-in. dTAG Degraders are heterobifunctional, comprising a synthetic ligand (AP1836), that selectively binds FKBP12F36V linked to an E3 ligase ligand, such as Thalidomide. The dTAG Degrader recruits the fusion protein to the E3 ligase complex, bringing about its ubiquitination and subsequent degradation by the proteasome.

In the aTAG (Achilles TAG) system, the protein of interest is expressed as a fusion with the enzyme MTH1 (MutT homolog-1; NUDT1). MTH1 is used as the TAG since there is no known phenotypic consequence resulting from the loss of this protein. The aTAG Degrader comprises a ligand selective for MTH1 linked to an E3 ligase ligand. As with dTAG, aTAG Degraders provide potent and rapid degradation of the fusion protein, and have a range of properties suitable for in vitro and in vivo applications. For more information on the CRIPSR-mediated knock-in of MTH1 fusion proteins, see accompanying Protocol.

TAG Technology for Target Validation

dTAG - for Target Validation

Figure 1: Schematic showing the mode of action of dTAG/aTAG Degraders. A protein of interest is expressed as a fusion with a "TAG" protein. For the dTAG system the protein of interest is tagged with F36V single-point mutated FKBP12; the aTAG system uses MTH1 as the TAG. The dTAG/aTAG Degrader initiates the formation of a ternary complex between an E3 ubiquitin ligase and the fusion protein which results in polyubiquitination of the target protein, its recognition by the proteasome and subsequent degradation of the entire protein. dTAG/aTAG molecules act catalytically, repeatedly engaging and directing the ubiquitination of target molecules.

Plasmid vectors for the lentiviral expression and CRISPR-mediated knock-in of FKBP12F36V are available from Addgene.

Literature for TAG Degradation Platform

Tocris offers the following scientific literature for TAG Degradation Platform to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Targeted Protein Degradation

Targeted Protein Degradation Research Product Guide

This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:

  • Active Degraders (e.g. PROTACs)
  • Degrader Building Blocks
  • Custom Degrader Services
  • UPS Proteins and Assays
  • Assays for Protein Degradation
Targeted Protein Degradation

Targeted Protein Degradation Poster

Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia